more

Illumina (ILMN)

(Real Time Quote from BATS)

$153.22 USD

+3.46 (2.31%)

Updated Nov 4, 2024 01:07 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Witnesses the Best August in 4 Years: 5 Top Picks

by Nalak Das Published on September 03,2018

Wall Street???s robust performance in August was fueled by strong second-quarter 2018 earnings results and solid macro-economic data like GDP, retail sales, consumer confidence and job data.

Vertex Inks Deal With Genomics to Make Serious Disease Drugs

by Zacks Equity Research Published on August 31,2018

Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.

4 of the Best Efficient Stocks to Enrich Your Portfolio

by Tirthankar Chakraborty Published on August 31,2018

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

by Zacks Equity Research Published on August 31,2018

Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

Stryker (SYK) to Acquire K2M Group, Fortify Spine Division

by Zacks Equity Research Published on August 31,2018

Post the acquisition, Stryker (SYK) will leverage on K2M Group's (KTWO) complex spine and minimally invasive solutions.

Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)

by Zacks Equity Research Published on August 30,2018

Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

by Zacks Equity Research Published on August 30,2018

Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

by Zacks Equity Research Published on August 30,2018

AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

by Zacks Equity Research Published on August 30,2018

Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

Patterson Companies (PDCO) Misses Q1 Earnings Estimates

by Zacks Equity Research Published on August 30,2018

Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.